within Pharmacolibrary.Drugs.ATC.B;

model B01AB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 1.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2850 / 1000000,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Nadroparin is a low molecular weight heparin (LMWH) used for the prevention and treatment of thromboembolic diseases, such as deep vein thrombosis and pulmonary embolism. It acts as an anticoagulant by potentiating the inhibition of factor Xa and to a lesser extent thrombin. Nadroparin is widely used and approved in many countries for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers after subcutaneous administration.</p><h4>References</h4><ol><li><p>Romano, LGR, et al., &amp; Preijers, T (2023). Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. <i>British journal of clinical pharmacology</i> 89(5) 1617–1628. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15634&quot;>10.1111/bcp.15634</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36495312/&quot;>https://pubmed.ncbi.nlm.nih.gov/36495312</a></p></li><li><p>Piwowarczyk, P, et al., &amp; Czuczwar, M (2023). Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19. <i>Clinical pharmacokinetics</i> 62(6) 835–847. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01244-4&quot;>10.1007/s40262-023-01244-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37097604/&quot;>https://pubmed.ncbi.nlm.nih.gov/37097604</a></p></li><li><p>Sytema, JG, et al., &amp; van Hulst, M (2023). The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin. <i>Research and practice in thrombosis and haemostasis</i> 7(4) 100185–None. DOI:<a href=&quot;https://doi.org/10.1016/j.rpth.2023.100185&quot;>10.1016/j.rpth.2023.100185</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37449055/&quot;>https://pubmed.ncbi.nlm.nih.gov/37449055</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AB06;
